Clinical and Translational Allergy

Table 2 Breast milk TGF-β concentrations in the probiotic and placebo groups at 10 days and 3 months postpartum

From: Atopic dermatitis prevention in children following maternal probiotic supplementation does not appear to be mediated by breast milk TSLP or TGF-β

	Days	Treatment				p^a
		Probiotic		Placebo
		n	Median (IQR) (pg/mL)	n	Median (IQR) (pg/mL)
TGF-β₁	10	128	616.9 (407.5–950.4)	127	617.3 (369.7–853.9)	0.34 0.33
	90	123	438.5 (308.0–661.1)	124	417.4 (269.3–641.8)	0.27 0.23
TGF-β₂	10	128	909.8 (451.6–1653.8)	127	999.4 (519.0–1517.1)	0.90 0.83
	90	123	599.6 (311.0–1055.1)	124	532.5 (285.9–1144.2)	0.76 0.69
TGF-β₃	10	128	37.8 (25.3–58.7)	127	35.8 (22.9–57.2)	0.25 0.33
	90	123	29.9 (21.0–42.7)	123	30.8 (18.8–48.7)	0.95 0.86

^aThe upper p-value provided is from the regression analysis of the influence of probiotic ingestion on the log transformed TGF beta concentration by, whilst the lower represents the p-value calculated for the effect of treatment allocation after adjusting for maternal atopy, maternal smoking and presence of siblings

Back to article page

ISSN: 2045-7022

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com